Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
+0.41 (7.09%)
After Hours: 6.27 +0.08 (1.29%)
Feb 11, 5:23PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.86 - 6.36
52 week 4.50 - 10.83
Open 6.11
Vol / Avg. 0.00/2.35M
Mkt cap 441.82M
P/E     -
Div/yield     -
EPS -0.31
Shares 72.18M
Beta 2.43
Inst. own 35%
Mar 14, 2016
Q4 2015 Inovio Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 23.13% -345.61%
Operating margin 15.43% -377.71%
EBITD margin - -362.17%
Return on average assets 10.38% -32.84%
Return on average equity 12.01% -44.14%
Employees 106 -
CDP Score - -


10480 Wateridge Cir
SAN DIEGO, CA 92121-5773
United States - Map
+1-858-5976006 (Phone)
+1-858-4041392 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio's immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Nancy J. Wysenski Director
Age: 57
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Morton Collins Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters